¼¼°èÀÇ ¹Ý°íÇü Á¦Á¦ À§Å¹»ý»ê ½ÃÀå
Semi-Solid Dosage Contract Manufacturing
»óǰÄÚµå : 1777544
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 383 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹Ý°íÇü Á¦Á¦ À§Å¹»ý»ê ¼¼°è ½ÃÀåÀº 2030³â±îÁö 353¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 189¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹Ý°íÇü Á¦Á¦ À§Å¹»ý»ê ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 11.0%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 353¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿Ü¿ëÁ¦´Â CAGR 10.3%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 181¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °æÇÇ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 12.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 51¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 14.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹Ý°íÇü Á¦Á¦ À§Å¹»ý»ê ½ÃÀåÀº 2024³â¿¡ 51¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 72¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 14.8%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 8.0%¿Í 9.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 8.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹Ý°íÇü Á¦Á¦ À§Å¹»ý»ê ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹Ý°íÇü Á¦Á¦ À§Å¹»ý»êÀÌ Á¦¾à ¾÷°è¿¡¼­ ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â?

¹Ý°íÇü Á¦Á¦ À§Å¹»ý»ê ½ÃÀåÀº Á¦¾à±â¾÷ÀÇ Àü¹® À§Å¹»ý»ê¾÷ü¿¡ ´ëÇÑ »ý»ê À§Å¹ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È®´ëµÇ°í ÀÖ½À´Ï´Ù. Å©¸², Á©, ¿¬°í, ¿¬°í, ÆäÀ̽ºÆ®¿Í °°Àº ¹Ý°íü Á¦Á¦´Â °íµµÀÇ Á¦Çü Àü¹® Áö½Ä, Á¤±³ÇÑ Àåºñ, ¾ö°ÝÇÑ ±ÔÁ¦ Áؼö°¡ ÇÊ¿äÇÕ´Ï´Ù. À§Å¹»ý»ê±â°ü(CMO)Àº ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇϰí, Á¦¾àȸ»ç´Â °íǰÁúÀÇ Á¦Á¶¸¦ º¸ÀåÇϸ鼭 ¿¬±¸, ¸¶ÄÉÆÃ, À¯Åë¿¡ ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇǺΰú Ä¡·áÁ¦, °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ, ±¹¼Ò ÁøÅëÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¹Ý°íü Á¦Çü¿¡ ´ëÇÑ Àü¹®¼ºÀ» ÇÊ¿ä·Î ÇÏ´Â ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ÂÃãÇü ÀÇ·á¿Í ¹æÃâÁ¦¾î Á¦Á¦ÀÇ µîÀåÀ¸·Î ¹Ý°íü Á¦Á¦ À§Å¹»ý»êÀÇ ¹üÀ§°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

¾î¶² ±â¼ú Çõ½ÅÀÌ ¹Ý°íü Á¦Á¦ Á¦Á¶¸¦ ¹ßÀü½Ã۰í Àִ°¡?

À¯È­ ±â¼ú, ¸¶ÀÌÅ©·Îĸ½¶È­, ÁöÁú ±â¹Ý ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀüÀ¸·Î ¹Ý°íü Á¦Á¦ÀÇ ¾ÈÁ¤¼º°ú È¿´ÉÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. AI¸¦ ÅëÇÑ ¿¹Ãø ¸ðµ¨¸µÀº Á¦Á¦ ÃÖÀûÈ­¸¦ °­È­Çϰí, °³¹ßÀÇ ½ÃÇàÂø¿À¸¦ ÁÙÀ̰í ÀÖ½À´Ï´Ù. ¿¬¼Ó »ý»ê °øÁ¤ÀÇ ÅëÇÕÀº »ý»ê È¿À²À» ³ôÀ̰í, ¹èÄ¡ °£ ÆíÂ÷¸¦ ÁÙÀ̸ç, ±ÔÁ¦ Ç¥ÁØÀ» ÁؼöÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ³ª³ë¿¡¸ÖÀü ±â¼úÀÇ Çõ½ÅÀº °æÇÇ ¹× ÇǺΰúÇÐÀû ÀÀ¿ë ºÐ¾ß¿¡¼­ ¾à¹°ÀÇ Èí¼ö¼º°ú »ýü ÀÌ¿ë·üÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ ¹ßÀüÀ¸·Î ¹Ý°íü Á¦Á¦ À§Å¹ »ý»êÀº º¸´Ù Á¤È®Çϰí È®Àå °¡´ÉÇÏ¸ç ºñ¿ë È¿À²ÀûÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¹Ý°íÇü Á¦Á¦ À§Å¹»ý»êÀÇ ¼ö¿ä¸¦ ÁÖµµÇÏ´Â Ä¡·á ºÐ¾ß´Â?

ÇǺΰú ºÐ¾ß´Â °Ç¼±, ½ÀÁø, ¿©µå¸§, ¿©µå¸§, °õÆÎÀÌ °¨¿°ÁõÀÇ Ä¡·á ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ¹Ý°íü À§Å¹»ý»êÀÇ ÁÖ¿ä °ßÀÎÂ÷ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. °æÇÇ ¾à¹°Àü´Þ ºÐ¾ßµµ ¼ºÀåÇϰí ÀÖÀ¸¸ç, ȯÀÚµéÀº °æ±¸¾àÀ̳ª ÁÖ»çÁ¦¸¦ ´ëüÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀû Ä¡·á¹ýÀ» ¿øÇϰí ÀÖ½À´Ï´Ù. È£¸£¸ó ´ëü¿ä¹ý(HRT), ÅëÁõ °ü¸® Å©¸², »óó °ü¸® Á¦Ç° µîÀº À§Å¹ Á¦Á¶ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀϹÝÀǾàǰ(OTC) ½ºÅ²ÄÉ¾î ¹× ÄÚ½º¸Þ½´Æ¼Äà Á¦Ç°ÀÇ Áõ°¡´Â ¹Ý°íü Á¦Á¦ Àü¹® CMOÀÇ ºñÁî´Ï½º ±âȸ¸¦ È®´ëÇϰí ÀÖ½À´Ï´Ù.

¹Ý°íÇü Á¦Á¦ À§Å¹»ý»ê ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¹Ý°íÇü Á¦Á¦ À§Å¹»ý»ê ½ÃÀåÀÇ ¼ºÀåÀº Á¦¾à ¾÷°èÀÇ ¾Æ¿ô¼Ò½Ì Æ®·»µå Áõ°¡, ÇǺΰú Ä¡·á ¹× °æÇÇÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Á¦Á¦ °úÇÐÀÇ ±â¼ú ¹ßÀüÀÌ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. FDA, EMA µî ±ÔÁ¦±â°üÀº ¾ö°ÝÇÑ Ç°Áú °ü¸®¿Í GMP Áؼö¸¦ °­Á¶Çϰí ÀÖÀ¸¸ç, Á¦¾à»çµéÀº Àü¹® CMO¿Í Á¦ÈÞ¸¦ ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦³×¸¯ ¹× OTC ÀǾàǰÀÇ È®´ë´Â È®Àå °¡´ÉÇÏ°í ºñ¿ë È¿À²ÀûÀÎ Á¦Á¶ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹Ý°íü ¾à¹°Àü´ÞÀÇ ±â¼ú Çõ½ÅÀÌ ÁøÇàµÊ¿¡ µû¶ó À§Å¹ Á¦Á¶´Â ÀǾàǰ °ø±Þ¸Á¿¡¼­ Á¡Á¡ ´õ Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

À¯Çü(±¹¼Ò, °æÇÇ, °æ±¸), Á¦Ç°(Å©¸², ¿¬°í, °Ö, ·Î¼Ç, ÆäÀ̽ºÆ®, ±âŸ), ÃÖÁ¾»ç¿ëÀÚ(Á¦¾àȸ»ç, È­Àåǰ ȸ»ç, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Semi-Solid Dosage Contract Manufacturing Market to Reach US$35.3 Billion by 2030

The global market for Semi-Solid Dosage Contract Manufacturing estimated at US$18.9 Billion in the year 2024, is expected to reach US$35.3 Billion by 2030, growing at a CAGR of 11.0% over the analysis period 2024-2030. Topical, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$18.1 Billion by the end of the analysis period. Growth in the Transdermal segment is estimated at 12.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 14.8% CAGR

The Semi-Solid Dosage Contract Manufacturing market in the U.S. is estimated at US$5.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.2 Billion by the year 2030 trailing a CAGR of 14.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 9.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.7% CAGR.

Global Semi-Solid Dosage Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Is Semi-Solid Dosage Contract Manufacturing Gaining Traction In The Pharmaceutical Industry?

The semi-solid dosage contract manufacturing market is expanding as pharmaceutical companies increasingly outsource production to specialized contract manufacturers. Semi-solid formulations, including creams, gels, ointments, and pastes, require advanced formulation expertise, sophisticated equipment, and stringent regulatory compliance. Contract manufacturing organizations (CMOs) offer cost-effective solutions, enabling pharmaceutical companies to focus on research, marketing, and distribution while ensuring high-quality manufacturing. The growing demand for dermatological treatments, transdermal drug delivery systems, and topical pain relief medications is driving the need for specialized semi-solid formulation expertise. Additionally, the rise of personalized medicine and controlled-release formulations is expanding the scope of semi-solid dosage contract manufacturing.

What Technological Innovations Are Advancing Semi-Solid Dosage Manufacturing?

Advancements in emulsification technology, microencapsulation, and lipid-based drug delivery systems are improving the stability and efficacy of semi-solid formulations. AI-driven predictive modeling is enhancing formulation optimization, reducing trial-and-error in development. The integration of continuous manufacturing processes is increasing production efficiency, reducing batch-to-batch variability, and ensuring better compliance with regulatory standards. Additionally, innovations in nano-emulsion technology are improving drug absorption and bioavailability in transdermal and dermatological applications. These technological advancements are making semi-solid dosage contract manufacturing more precise, scalable, and cost-effective.

Which Therapeutic Areas Are Driving Demand For Semi-Solid Dosage Contract Manufacturing?

The dermatology sector is a major driver of semi-solid contract manufacturing, with increasing demand for treatments for psoriasis, eczema, acne, and fungal infections. The transdermal drug delivery segment is also growing, with patients seeking non-invasive alternatives to oral and injectable medications. Hormone replacement therapy (HRT), pain management creams, and wound care products are further driving demand for contract manufacturing services. Additionally, the rise of over-the-counter (OTC) skincare and cosmeceutical products is expanding opportunities for CMOs specializing in semi-solid formulations.

What Factors Are Fueling The Growth Of The Semi-Solid Dosage Contract Manufacturing Market?

The growth of the semi-solid dosage contract manufacturing market is driven by increasing outsourcing trends in the pharmaceutical industry, rising demand for dermatological and transdermal treatments, and technological advancements in formulation science. Regulatory agencies such as the FDA and EMA are emphasizing stringent quality control and GMP compliance, prompting pharmaceutical companies to partner with specialized CMOs. Additionally, the expansion of generic and OTC pharmaceutical products is fueling demand for scalable and cost-effective manufacturing solutions. As innovation in semi-solid drug delivery continues, contract manufacturing will play an increasingly vital role in the pharmaceutical supply chain.

SCOPE OF STUDY:

The report analyzes the Semi-Solid Dosage Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Topical, Transdermal, Oral); Product (Creams, Ointments, Gels, Lotions, Pastes, Others); End-Use (Pharmaceutical Companies, Cosmeceutical Companies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â